1. Home
  2. WB vs MESO Comparison

WB vs MESO Comparison

Compare WB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weibo Corporation

WB

Weibo Corporation

HOLD

Current Price

$9.99

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.07

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WB
MESO
Founded
2009
2004
Country
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WB
MESO
Price
$9.99
$17.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$14.00
N/A
AVG Volume (30 Days)
1.0M
202.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
16.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.53
$633.98
Revenue Next Year
$2.38
$29.51
P/E Ratio
$5.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.10
$9.61
52 Week High
$12.96
$21.50

Technical Indicators

Market Signals
Indicator
WB
MESO
Relative Strength Index (RSI) 39.72 46.75
Support Level $9.70 $16.50
Resistance Level $10.37 $18.38
Average True Range (ATR) 0.30 0.58
MACD -0.06 -0.02
Stochastic Oscillator 20.80 51.70

Price Performance

Historical Comparison
WB
MESO

About WB Weibo Corporation

Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: